• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 3. Exclusive self-aligned β-phase PVDF films with abnormal piezoelectric coefficient prepared via phase inversion?
  N. Soin,D. Boyer,K. Prashanthi,S. Sharma,A. A. Narasimulu,J. Luo,T. H. Shah,E. Siores,T. Thundat Chem. Commun., 2015,51, 8257-8260
• 4. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Recent Advances in the Study of 6,7-Dimethoxy-2,4-quinazolinediamine (CAS: 60547-96-8)

6,7-Dimethoxy-2,4-quinazolinediamine (CAS: 60547-96-8) is a quinazoline derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This compound, characterized by its dimethoxy and diamine functional groups, has been explored for its diverse biological activities, including kinase inhibition, antimicrobial properties, and potential anticancer effects. The unique structural features of this molecule make it a promising scaffold for the design of novel therapeutic agents.

Recent studies have focused on elucidating the molecular mechanisms underlying the biological activities of 6,7-Dimethoxy-2,4-quinazolinediamine. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent inhibitory activity against certain tyrosine kinases, which are critical targets in cancer therapy. The researchers employed molecular docking and kinetic assays to characterize the binding interactions, revealing a high affinity for the ATP-binding sites of these kinases. These findings suggest that 6,7-Dimethoxy-2,4-quinazolinediamine could serve as a lead compound for the development of new kinase inhibitors.

In addition to its kinase inhibitory properties, 6,7-Dimethoxy-2,4-quinazolinediamine has shown promising antimicrobial activity. A 2022 study in the European Journal of Medicinal Chemistry reported that this compound exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria, with minimum inhibitory concentrations (MICs) comparable to some clinically used antibiotics. The study also highlighted the compound's ability to disrupt bacterial cell membrane integrity, providing insights into its mechanism of action. These results underscore the potential of 6,7-Dimethoxy-2,4-quinazolinediamine as a candidate for combating antibiotic-resistant pathogens.

The synthesis and optimization of 6,7-Dimethoxy-2,4-quinazolinediamine derivatives have also been a focus of recent research. A 2023 paper in Bioorganic & Medicinal Chemistry Letters described a series of structural modifications aimed at enhancing the compound's bioavailability and therapeutic efficacy. The authors reported that certain derivatives exhibited improved pharmacokinetic profiles and reduced cytotoxicity, making them more suitable for in vivo applications. These advancements highlight the potential for further development of this compound class.

Despite these promising findings, challenges remain in the clinical translation of 6,7-Dimethoxy-2,4-quinazolinediamine. Issues such as solubility, metabolic stability, and off-target effects need to be addressed through further structural optimization and preclinical studies. Nonetheless, the growing body of research on this compound underscores its potential as a versatile scaffold for drug discovery. Future studies should focus on expanding the understanding of its pharmacological properties and exploring its applications in other therapeutic areas, such as neurodegenerative diseases and inflammation.

• 19216-68-3(6,7-dimethoxy-N~2~,N~2~-dimethylquinazoline-2,4-diamine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)